Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Conflict of interest

KCK serves as consultant to Philogen, BMS, MSD, Sanofi Aventis, Immunocore and received travel grants and speaker fees from Philogen, Pierre Fabre, BMS, MSD, Sun Pharma, Sanofi Aventis, Novartis, Medac and has received research support by Novartis. RG reports grants or contracts from Novartis, Sun Pharma, Amgen, Sanofi, Merck-Serono, Kyowa-Kirin, and Almirall-Hermal; payment or honoraria for lectures, presentation, manuscript writing or educational events from Roche Pharma, Bristol Myers Squibb, Novartis, Merck Sharp & Dohme, Almirall-Hermal, Amgen, and Merck-Serono; support for attending meetings and/or travel from Sun Pharma, Pierre Fabre, and Boehringer-Ingelheim; participation on a data safety monitoring board or advisory board for Roche Pharma, Bristol Myers Squibb, Novartis, Merck Sharp & Dohme, Almirall-Hermal, Amgen, Pierre Fabre, Merck-Serono, Sun Pharma, Merck-Serono, Sanofi, 4SC and Immunocore. YA received honoraria and travel grants from BMS, MSD, Novartis, Almirall Hermal, SUN, Sanofi, Pierre-Fabre. EL served as consultant and/or has received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre-Fabre, Sanofi, Sunpharma, Takeda and travel support from Bristol-Myers Squibb, Pierre- Fabre, Sunpharma and Novartis, outside the submitted work. GL received travel support from Sun Pharma, Pierre Fabre, research funding from Novartis. FM served as consultant and/or has received honoraria from Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Sanofi Genzyme, Sun Pharma and travel support from Novartis, Sun Pharma, Pierre Fabre and Merck Sharp & Dohme, outside the submitted work. DARS served as consultant and/or has received honoraria from BMS, MSD, Pierre Fabre, Sanofi Genzyme, Roche, Novartis, Sun Pharma. SWF has no conflicts. DN has no conflicts. CL served for advisory Boards and received speakers fees and travel reimbursement from BMS, MSD, Merck, Almirall Hermal, Sanofi, Immunocore, Sun Pharma, Biontech, Pierre Fabre, Merck, Novartis. JCH served for advisory boards and received speakers fees and travel reimbursement from Amgen, BMS, Delcath, GSK, Immunocore, MSD, Novartis, Onkowissen, Pierre Fabre, Sanofi, Sunpharma. MMS has received consulting fees from Novartis and Sanofi. LVM has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by Almirall, Amgen, Eli Lilly, Incyte, MSD, Novartis, Pierre Fabre, Roche, and Sanofi outside of the current work. LH Lucie Heinzerling declares speakers and advisory board honoraria from Bristol-Myers Squibb GmbH & Co. KGaA, Immunocore Ireland Ltd, Kyowa Kirin GmbH, MSD Sharp & Dohme GmbH, Novartis Pharma GmbHm Pieris Pharmaceuticals, Pierre Fabre Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Stemline Therapeutics Switzerland GmbH, SUN Pharmaceutical Europe Industries BV, Therakos (UK) LTD. Patents: IL-12 plasmid DNA; VEGF-D for lymphangiogenesis; soluble prognostic marker for melanoma. Clinical studies within the institution: Agenus, AstraZeneca Inc., Bristol Myers Squibb, Huya Bioscience, IO Biotech, Merck Sharp & Dohme GmbH, Pfizer, Pierre Fabre, Regeneron, Replimune, Sanofi Aventis. MVH has received honoraria from Sanofi, Almirall, Biofrontera, Galderma, Novartis, BMS, MSD, Roche, Immunocore, Sun Pharmaceuticals, Pierre Fabre. CC has no conflicts. JR has no conflicts. CB has received speaker honoraria, research grants and/or awards from Amgen/Celgene, AstraZeneca, Bauerfeind, Hartmann, Helios Klinik Leisnig, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Pfizer, Stiefel Laboratories, The EuroQol Group, UCB, and Urgo.